Tubilux Pharma Spa – FDA 483, Dec 2, 2019
Tubilux Pharma Spa in Pomezia, Italy, received a Form 483 with four observations during an FDA inspection from December 2-10, 2019. The inspection revealed significant issues across quality systems, including inadequate review of biological indicator data for sterile products, deficient complaint investigations for packaging malfunctions, and failures within the quality control unit regarding viscosity test evaluations and supplier controls. These findings indicate a moderate level of concern regarding the firm's adherence to cGMPs for drug manufacturing.
ID · 6d9db35b-df99-4eae-9199-56bea218c80d
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.